Emergent Biosolutions Inc.

32.76+0.4200+1.30%Vol 770.27K1Y Perf -47.71%
Jun 24th, 2022 16:00 DELAYED
BID30.03 ASK34.50
Open32.85 Previous Close32.34
Pre-Market- After-Market33.72
 - -  0.96 2.93%
Target Price
44.50 
Analyst Rating
Moderate Buy 2.20
Potential %
35.84 
Finscreener Ranking
★★★+     50.72
Insiders Trans % 3/6/12 mo.
-100/-100/-33 
Value Ranking
★★★★+     58.29
Insiders Value % 3/6/12 mo.
-100/-100/2 
Growth Ranking
★★★★+     62.40
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-3 
Income Ranking
 —    -
Price Range Ratio 52W %
14.35 
Earnings Rating
Strong Buy
Market Cap1.65B 
Earnings Date
4th Aug 2022
Alpha-0.00 Standard Deviation0.12
Beta0.98 

Today's Price Range

31.9533.15

52W Range

26.8568.03

5 Year PE Ratio Range

5.30133.60

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
14.75%
1 Month
-2.90%
3 Months
-25.88%
6 Months
-28.03%
1 Year
-47.71%
3 Years
-30.46%
5 Years
-5.45%
10 Years
122.40%

TickerPriceChg.Chg.%
EBS32.760.42001.30
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Earnings HistoryEstimateReportedSurprise %
Q01 20220.240.18-25.00
Q04 20213.894.5015.68
Q03 20212.03-0.36-117.73
Q02 20211.810.33-81.77
Q01 20210.971.5357.73
Q04 20202.723.6734.93
Q03 20202.052.196.83
Q02 20200.531.98273.58
Earnings Per EndEstimateRevision %Trend
6/2022 QR0.6380.00Positive
9/2022 QR0.39-40.91Negative
12/2022 FY1.02-45.74Negative
12/2023 FY2.48-56.49Negative
Next Report Date4th Aug 2022
Estimated EPS Next Report0.63
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume770.27K
Shares Outstanding50.24K
Shares Float31.86M
Trades Count10.30K
Dollar Volume25.14M
Avg. Volume732.68K
Avg. Weekly Volume746.81K
Avg. Monthly Volume717.97K
Avg. Quarterly Volume733.27K

Emergent Biosolutions Inc. (NYSE: EBS) stock closed at 32.76 per share at the end of the most recent trading day (a 1.3% change compared to the prior day closing price) with a volume of 770.27K shares and market capitalization of 1.65B. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 2200 people. Emergent Biosolutions Inc. CEO is Robert G. Kramer.

The one-year performance of Emergent Biosolutions Inc. stock is -47.71%, while year-to-date (YTD) performance is -24.64%. EBS stock has a five-year performance of -5.45%. Its 52-week range is between 26.85 and 68.0281, which gives EBS stock a 52-week price range ratio of 14.35%

Emergent Biosolutions Inc. currently has a PE ratio of 9.80, a price-to-book (PB) ratio of 0.91, a price-to-sale (PS) ratio of 0.82, a price to cashflow ratio of 5.40, a PEG ratio of 2.32, a ROA of 5.55%, a ROC of 7.57% and a ROE of 10.17%. The company’s profit margin is 8.96%, its EBITDA margin is 21.90%, and its revenue ttm is $1.76 Billion , which makes it $34.97 revenue per share.

Of the last four earnings reports from Emergent Biosolutions Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $0.63 for the next earnings report. Emergent Biosolutions Inc.’s next earnings report date is 04th Aug 2022.

The consensus rating of Wall Street analysts for Emergent Biosolutions Inc. is Moderate Buy (2.2), with a target price of $44.5, which is +35.84% compared to the current price. The earnings rating for Emergent Biosolutions Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Emergent Biosolutions Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Emergent Biosolutions Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 17.27, ATR14 : 1.84, CCI20 : 66.15, Chaikin Money Flow : 0.04, MACD : -0.72, Money Flow Index : 61.43, ROC : 1.17, RSI : 54.72, STOCH (14,3) : 93.81, STOCH RSI : 1.00, UO : 63.92, Williams %R : -6.19), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Emergent Biosolutions Inc. in the last 12-months were: Kathryn C. Zoon (Sold 3 169 shares of value $107 891 ), Richard S. Lindahl (Buy at a value of $112 380)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (40.00 %)
2 (40.00 %)
3 (50.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
3 (60.00 %)
3 (60.00 %)
3 (50.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
2.20
Moderate Buy
2.20
Moderate Buy
2.00

Emergent Biosolutions Inc.

Emergent BioSolutions offers public health products to government and healthcare providers. The company has four main units: vaccines, which produces specialty vaccines for public health threats; devices, such as nasal sprays, skin lotions, and injections; therapeutics, which includes antibody-based treatments; and contract development and manufacturing, which brings treatments to market through collaboration with the pharmaceutical and biotechnology industries and the United States government. Most revenue comes from U.S. government purchases of vaccine, device, and therapeutic products.

CEO: Robert G. Kramer

Telephone: +1 240 631-3200

Address: 400 Professional Drive, Gaithersburg 21079, MD, US

Number of employees: 2 200

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

60%40%

Bearish Bullish

59%41%

Bearish Bullish

56%44%

TipRanks News for EBS

Fri, 29 Apr 2022 11:25 GMT Analysts Top Healthcare Picks: Emergent Biosolutions (EBS), Viking Therapeutics (VKTX)

- TipRanks. All rights reserved.

News

Stocktwits